[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100599565":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":24,"locations":30,"responsibleParty":64,"collaborators":18,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":18,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":18,"maxAge":75,"enrollmentInfo":76,"targetDuration":18,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":33,"whyStopped":18,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Azienda Ospedaliero, Universitaria Ospedali Riuniti","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Myocarditis Panel","EXPERIMENTAL","N=15 patients from 2025, in which management and treatment of arrhythmias and or myocardial dysfunction were driven by the panel",[13],"Diagnostic Test: Determination of viral genome, bacterial serology, and markers of inflammation in pediatrics diagnosed with myocarditis",{"label":15,"type":16,"description":17,"interventionNames":18},"No Panel","NO_INTERVENTION","The 15 patients managed and treated for arrhythmias or myocardial dysfunction in 2024 without applying the myocarditis panel",null,[20],{"type":21,"name":22,"description":11,"armGroupLabels":23,"otherNames":18},"DIAGNOSTIC_TEST","Determination of viral genome, bacterial serology, and markers of inflammation in pediatrics diagnosed with myocarditis",[9],[25],{"name":26,"role":27,"phone":28,"phoneExt":18,"email":29},"Francesco Bianco, M.D., Ph.D., MSc, FEACVI","CONTACT","+39 071 596 5527","francesco.bianco@ospedaliriuniti.marche.it",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Francesco Bianco","RECRUITING","Ancona","The Marches","60126","Italy","IT",{"type":40,"coordinates":41},"Point",[42,43],13.5103,43.60717,{"lat":43,"lon":42},[46,49,52,54,56,58,60,62],{"name":47,"role":27,"phone":48,"phoneExt":18,"email":29},"Francesco Bianco, M.D., Ph.D., MSc., FEACVI","+ 39 071 596 5527",{"name":50,"role":51,"phone":18,"phoneExt":18,"email":18},"Federica Zallocco, M.D.","SUB_INVESTIGATOR",{"name":53,"role":51,"phone":18,"phoneExt":18,"email":18},"Bianca Lattanzi, M.D., Ph.D.",{"name":55,"role":51,"phone":18,"phoneExt":18,"email":18},"Alessia Omenetti, M.D., Ph.D.",{"name":57,"role":51,"phone":18,"phoneExt":18,"email":18},"Francesca C. Surace, M.D.",{"name":59,"role":51,"phone":18,"phoneExt":18,"email":18},"Emanuela Berton, M.D.",{"name":61,"role":51,"phone":18,"phoneExt":18,"email":18},"Alessandra Palpacelli, M.D.",{"name":63,"role":51,"phone":18,"phoneExt":18,"email":18},"Valentina Bucciarelli, M.D., Ph.D.",{"type":65,"investigatorFullName":32,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Principal investigator","100599565","efficacy-of-a-myocardial-panel-in-the-management-and-treatment-of-pediatric-myocarditis-100599565",false,"NCT07086144","Efficacy of a Myocardial Panel in the Management and Treatment of Pediatric Myocarditis","Efficacy of a Myocardial Panel (Virological, Bacterial and Autoimmune) in the Management and Treatment of Pediatric Myocarditis Complicated With Arrhythmias or Ventricular Dysfunction","Inclusion Criteria:\n\n* All the consecutive pediatric patients (\\\u003C 18 years old) presenting with myocarditis complicated by arrhythmias or myocardial dysfunction\n\nExclusion Criteria:\n\n* Refused consent to be included in the study given by parents or legal tutors\n* Uncomplicated myocarditis presenting without arrhythmias or myocardial dysfunction","ALL","18 Years",{"count":77,"type":78},30,"ESTIMATED","INTERVENTIONAL",[81],"NA","The goal of this observational study is to determine the efficacy a of combined management and treatment driven by the systematic determination of viral genome, bacterial serology, and markers of inflammation in pediatric patients (\\\u003C 18 years old) diagnosed with myocarditis complicated by arrhythmias (supraventricular and ventricular tachycardias and heart block) or ventricular dysfunction (left ventricular ejection fraction \\\u003C 50% or right ventricular fractional area change \\\u003C 35%).\n\nThe main question it aims to answer is: Does this panel help resolve arrhythmias or myocardial dysfunction due to myocarditis during hospitalisation and follow-up?\n\nResearchers will compare patients managed and treated in 2024 without applying the myocarditis panel with those enrolled in 2025 who received the panel. Arrhythmias and myocardial dysfunction will be managed in accordance with recent guidelines. Antiviral, antibiotic or immunosuppressive therapies will be implemented in addition to standard therapy when required by the panel.",[84],"Myocarditis",[86,87,88,89,90],"pediatric myocarditis","Arrhythmias","Myocarditis panel","Etiological therapy","Myocardial dysfunction","2025-07-18",{"date":93,"type":94},"2025-07-25","ACTUAL",{"date":96,"type":94},"2024-01-01",{"date":98,"type":78},"2028-12-31",{"name":5,"class":6},1]